LEPU BIO-B: NOTICE OF 2025 FIRST EXTRAORDINARY GENERAL MEETING
LEPU BIO-B: PROXY FORM FOR USE AT THE 2025 FIRST EXTRAORDINARY GENERAL MEETING
LEPU BIO-B: (1) CONTINUING CONNECTED TRANSACTION IN RELATION TOCDMO SERVICES FRAMEWORK AGREEMENT(2) PROPOSED CHANGE OF THE AUDITORAND(3) NOTICE OF THE 2025 FIRST EXTRAORDINARY GENERALMEETING
LEPU BIO-B: CLOSURE OF REGISTER OF MEMBERS FORTHE 2025 FIRST EXTRAORDINARYGENERAL MEETINGS TO BE HELD ON JANUARY 7, 2025
LEPU BIO-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2024
LEPU BIO-B: CONTINUING CONNECTED TRANSACTIONCDMO SERVICES FRAMEWORK AGREEMENT
LEPU BIO-B: ANNOUNCEMENT OFPROPOSED CHANGE OF AUDITOR
LEPU BIO-B: CONTINUING CONNECTED TRANSACTIONNEW PROCUREMENT FRAMEWORK AGREEMENT
LEPU BIO-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2024
LEPU BIO-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2024
LEPU BIO-B: VOLUNTARY ANNOUNCEMENTACCEPTANCE OF THE NEW DRUG APPLICATION AND PRIORITYREVIEW GRANTED BY NMPA TOMRG003 FOR THE TREATMENT OF R/M NPC
LEPU BIO-B: 2024 Interim Report
LEPU BIO-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August 2024
LEPU BIO-B: ARTICLES OF ASSOCIATION
LEPU BIO-B: AMENDMENTS TO THE ARTICLES OF ASSOCIATION
LEPU BIO-B: INTERIM RESULTS ANNOUNCEMENTFOR THE SIX MONTHS ENDED JUNE 30, 2024
LEPU BIO-B: NOTICE OF BOARD MEETING
LEPU BIO-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July 2024
LEPU BIO-B: VOLUNTARY ANNOUNCEMENTBREAKTHROUGH THERAPY DESIGNATION GRANTEDBY THE FDA TO MRG003 FOR THE TREATMENT OF R/M NPC
LEPU BIO-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June 2024
No Data